Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb (BMS) has entered into an immunity-from-suit pact with Matrix Laboratories to manufacture and sell its HIV medicine Reyataz (atazanavir sulfate), stavudine and didanosine in sub-Saharan Africa and India.
Subscribe to our email newsletter
The agreement also includes pediatric formulations of the medicines for supporting the treatment needs of children with HIV.
As per the terms of the agreement, Matrix will receive prequalification from the World Health Organization (WHO) for all the products that are covered under the agreement.
Matrix also expects WHO prequalification for pediatric formulations of didanosine and, in the future, atazanavir powder formulation for pediatric use when BMS‘s product is available.
BMS Intercontinental Region president Frank Pasqualone said Atazanavir is an important component of HIV combination therapy and this agreement facilitates broader availability of the medicine to help ensure patients can access appropriate treatment regimens.